Gritstone bio Company Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases.
Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors.
The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors.
In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection.
Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH.
The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021.
Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California. On October 10, 2024, Gritstone bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
| Country | United States |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 231 |
| CEO | Andrew Allen |
Contact Details
Address: 5959 Horton Street EmeryVille, Delaware 94608 United States | |
| Phone | 510 871 6100 |
| Website | gritstonebio.com |
Stock Details
| Ticker Symbol | GRTSQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Erin E. Jones M.S. | Executive Vice President and Chief Operating Officer |
| Dr. Karin Jooss Ph.D. | Executive Vice President and Head of Research and Development |
| Vassiliki Economides | Executive Vice President and Chief Financial Officer |
| James Cho | Chief Accounting Officer |
| George E. MacDougall | Director of Investor Relations and Corporate Communications |
| Stacy Proctor | Executive Vice President and Chief People Officer |
| Dr. Matthew J. Hawryluk M.B.A., Ph.D. | Executive Vice President and Chief Business Officer |